SOPHiA GENETICS Reports Strong 2025 Results, Issues Positive 2026 Guidance, and Announces CEO Succession

summarizeSummary

SOPHiA GENETICS reported strong preliminary Q4 and full-year 2025 financial results, provided positive 2026 revenue guidance, and announced a planned CEO transition with Ross Muken succeeding co-Founder Jurgi Camblong.

check_boxKey Events

• Strong Preliminary 2025 Financial Results

  The company reported preliminary unaudited Q4 2025 revenue of at least $21 million, representing approximately 20% year-over-year growth, and full-year 2025 revenue of approximately $77 million, an 18% increase year-over-year. Over 391,000 analyses were performed on SOPHiA DDM™ in 2025, a new company record.

• Positive 2026 Revenue Guidance

  SOPHiA GENETICS initiated its full-year 2026 guidance, projecting revenue between $92 million and $94 million, which represents approximately 20% to 22% year-over-year growth. The company also expects an Adjusted EBITDA loss between $29 million and $32 million.

• Planned CEO Succession and Executive Transition

  Ross Muken, current President and a key executive for five years, will be promoted to Chief Executive Officer, effective July 1, 2026. Co-Founder Jurgi Camblong will transition to Executive Chairman of the Board, focusing on strategic initiatives and technology innovation. Additionally, Kevin Puylaert was appointed Chief Sales Officer, effective January 2026.

auto_awesomeAnalysis

SOPHiA GENETICS has provided a robust outlook for its business, reporting strong preliminary financial results for 2025 and projecting continued significant revenue growth for 2026. The planned CEO transition, with an experienced internal leader taking the helm and the co-founder moving to Executive Chairman, signals stability and a clear strategic path forward. This combination of sustained growth and smooth leadership succession is a positive indicator for the company's future trajectory, especially as the stock is trading near its 52-week high.